Transaction Report:
(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.)
Editor: Karin Dumstrei 1st Editorial Decision 07 December 2012
Thank you for submitting your manuscript to the EMBO Journal. Your study has now been seen by two referees and their comments are provided below.
As you can see both referees find the analysis interesting and are supportive of publication here. However they also both indicate that that the analysis needs to be extended in order to consider publication here. Should you be able to address the raised concerns then we would consider a revised manuscript. I should add that it is EMBO Journal policy to allow one major round of revision only and that it is therefore important to address the raised concerns at this stage.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline, please let us know in advance and we may be able to grant an extension.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
REFEREE REPORTS Referee #1
In this article, the authors report important new data on VAPB, an ER protein mutated in amyotrophic lateral sclerosis type 8 (VAPB-P56S mutation). The authors searched for VAPB partners by mass spectrometry identification of proteins bound to tagged VAPB in HeLa cells. They validate the appraoch by identifying known VAPB partners (several OSBPL) and found a new partner: Yif1A, a protein which recycle between the ER and the Golgi apparatus and is involved in the maintenance of the Golgi structure. The authors went on to characterize the function of VAPB in YifA localization into dendrites and dendritic morphology. Expression of VAPB-P56S further induced mislocalization of Yif1A.
The results are novel and of high interest for membrane trafficking and neurodegeneration. The experiments were well carried out and controlled.
A few additional data/comments would greatly improve this article: 1-ALS is characterized by progressive axonal dysfunction and recent data in fly showed that VAPB is involved in axonal expression of Down syndrome cell adhesion molecule. Here the authors only show dendritic defects. It would be important to also document in more details if there is or not an axonal phenotype (with specific markers) when impairing Yif1A and VAPB. 2-Yif1B was shown to mediate the traffic of 5HT receptors in dendrites. This raises the question whether the complex identified here is involved in the transport of specific proteins or more globally in the dendritic early secretory pathway. The effect on dendritic morphology does not answer the question because defect in the transport of specific proteins could be enough to induce the morphological defect. The authors should discuss this question.
Referee #2
VAPB is a multifunctional adaptor of the ER membrane. A large number of VAPB interacting partners have been reported, and two mutations (which generate the P56S and T46I protein products) are linked to familial ALS. In this study, the authors report a novel VAPB interactor, YIF1A, a transmembrane protein that recycles between the ER, the ERGIC, and the Golgi complex and that plays an important role in membrane trafficking at the ER/Golgi interface. Interestingly, the authors report that the interaction involves the VAPB and YIF1A transmembrane domains, and that the VAPs (A and B) are required for the ER localization of YIF1A. In the absence of the VAPs or in the presence of overexpressed VAPB, YIF1A's localization is shifted to the ERGIC/Golgi or to the ER, respectively. Furthermore, the authors report that silencing of either the VAPs or YIF1A causes a reduction of the dendritic tree and reduced membrane protein trafficking to dendrites in primary hippocampal neurons. Finally, since YIF1A interacts also with mutant (P56S) VAPB and remains trapped in the aggregates generated by the mutant protein, the authors suggest that interferance with ER to Golgi trafficking may partly account for the pathogenicity of ALS-linked P56S-VAPB.
This is an interesting study with novel observations that may shed light on the role of the VAPs in membrane traffic and that proposes an interesting disease mechanism of mutant, ALS-linked, VAPB. Despite the interest, I have several major concerns plus a number of minor points, which must be addressed before the paper is suitable for publication.
Major concern 1: Role of the transmembrane domains in the YIF1A-VAPB interaction. From the wording of the section "The transmembrane domains of both VAPB and YIF1A are required for their interaction" (p. 5), it is not clear to me whether the authors are concluding that there is a specific interaction between the TMs of the interacting proteins, or whether the TMs, by allowing insertion of the proteins into the ER membrane and restricting their diffusion to a two-dimensional space, simply facilitate their interaction. From Fig. 2E , it is clear that the N-terminal cytosolic portion of YIF1A by itself does not interact with ER-bound VAPB, while constructs carrying all four, or the last two, YIF1A TMs do. The contribution of the cytosolic and luminal loops in these constructs to this interaction is not considered; furthermore, one wonders how the GFP-YIF1A construct with the first two TMs (complementary to the one with the last two) will behave. Is there any sequence specificity? Similarly, the involvement of VAPB's TMD is inferred from from the pulldown of HA-YIFA by a construct in which GFP is fused to only the TMD of VAPB. It appears, however, that the pulldown of YIF1A by this construct is far less efficient than when the full-length VAPB is used as bait ( Fig. 2H and I ), suggesting that VAPB regions in the cytosolic domain are involved in the interaction. The control that is missing here is a VAPB construct with an unrelated TM. A useful experiment would be to express the P56S mutant containing an unrelated TM. Such constructs are known to form ER inclusion bodies; these should no longer be enriched in YIF1A if the interaction is crucially dependent on the VAP TMD. A further important question concerns the interaction of YIF1A with the VAPB homologue VAPA: in the experiments of Figs. 5, 7, and 8, the authors silence BOTH VAPA and B; presumably the double knockdown is necessary to observe effects on YIF1A localization and dendritic arborization. So, presumably, VAPA also interacts with YIF1A. However, this is not shown and there is not a great degree of sequence conservation between the TMs of the two VAP isoforms. Given the functional consequences of VAPA silencing, the interaction between VAPA and YIF1A should be analysed. Similar considerations could be applied to the YIF1B, which also appears to be recruited into P56S-VAPB aggregates (Fig. 1 ).
Major concern 2: Silencing experiments (Figs 5, 7, 8) . The results are interesting, but crucial controls are lacking. Only one shRNA is used for each silenced protein, so off-target effects cannot be excluded. To prove specificity, shRNA-resistant constructs would have to be co-expressed, or at least, it would be important to demonstrate that more than one shRNA obtains the same effects. Another problem is that the authors do not check by immunofluorescence how much of the endogenous target protein is knocked down. In the absence of this information, one cannot be sure that the cells selected for imaging have downregulated expression of the target protein, as the authors use expression of a co-transfected protein as criterion for selection of silenced cells. However, expression of shRNA and of the transfected protein may not be exactly parallel. A polycistronic pSUPER vector, encoding the shRNA along with GFP, should be used.
Other concerns: Role of VAP A/B, YIF1A/B and SAR1A/B in membrane trafficking to dendrites (Fig. 8) . Despite the fact that these experiments are carried out along the lines of work previously published in a prestigious journal (Ye B et al, Cell, 2007) , I find that the interpretation of the results is ambiguous. The authors analyse recovery from the soma of a surface protein bleached in a dendrite, and find that recovery is reduced after silencing of VAPA/B, YIF1A/B or SAR1A/B. The problem is that there is more than one source of the dendritic surface protein (CD8-GFP); one expects that in the cell body most of it is on the surface, so that recovery into dendrites would depend on diffusion from the cell body plasmamembrane to the dendritic plasma membrane; some CD8 may be intracellular but past the ER, and also in this case, one does not expect a role for proteins involved in ER to Golgi transport. About 65% of the dendritic CD8 fluorescence recovers in only 20 minutes under control conditions; it is difficult to think that over one third of this is due to vesicular transport, as would be suggested by the results in Sar1 silenced cells (Fig. 8C ). This would imply an extremely rapid turnover of dendritic CD8 (over 20% of dendritic CD8 replaced in 20 min). The authors could distinguish between surface exposed and intracellular CD8 by antibody staining of an extracellular epitope under permeabilizing and non-permeabilizing conditions. They could also empty the ER store by cycloheximide treatment, and do FRAP experiments under this condition. This would inform us of the rate of dendrite recovery in the absence of ER stores in the cell body, and would tell us whether the silencing of VAPs, YIFs, and SARs has any effect on post-Golgi trafficking or diffusion of CD8.
Minor: 1. Figures: Scale bars are never given (with the exception of Fig. 7 ). 2. In the pulldown experiments ( Fig. 2 ) the amount of input, compared to the pulled down material, is not specified. Why is the input lane of GFP-YIF1A(131-293) ( Fig. 2F ) empty? 3. GST-VAPB pulldown experiments ( Fig. 2H ): from the literature it is well known that VAPB-P56S is totally insoluble in non-denaturing detergents. Therefore, the use of glutathione beads to pull down this construct is completely unspecific, as the insoluble construct will pellet anyway, whether the beads are present or not. (Fig. 2B ) or Myc-VAPB-P56S (Supp. Fig. 1 ). In the latter case it looks like a truely soluble protein with accumulation in the nucleus; in the former case it looks as if it had a more vesicular localization and is excluded from the nucleus. This suggests that the N-terminal cytosolic domain of YIF1A may have a weak interaction with wildtype, but not mutant VAPB. Fig. 8D : The effect of VAP depletion is less pronounced than that of YIF1A/B and of Sar1A/B), although significantly different from the control by Student's t test (Fig. 8D ). Given that four groups are involved, it would be better to apply Anova analysis.
Abstract, Introduction p. 3, and Supplemental Figure 3 : the authors refer to the P56S-VAPB induced inclusion bodies as "tubular ER-like inclusions" . Recent work has shown that these inclusions correspond to packed cisternae and not to tubules (see Papiani G. et al., J. Cell Sci 2012 for the 3D reconstruction of these structures by tomography). Furthermore, FRAP experiments definitely demonstrated the continuity of these structures with the remaining ER (Fasana E. et al, FASEB J 2010) . Therefore, "tubular ER -like inclusion" does not correctly describe the structures. Similarly, the cartoon of Sup. Fig. 3 , which shows the mutant VAPB aggregate as separate from the remaining ER, is incorrect. Figure 9 and Discussion: the idea that one pathogenic mechanism of P56S-VAPB may be to trap YIF1A in aggregates and consequently interfere with ER to Golgi transport is very appealing. When discussing this idea, the authors should, however, recognize that they observe this trapping effect under conditions of high overexpression of the mutant protein, and that the relevance of this observation to the situation of the heterozygous human subject remains to be determined. We are pleased that Referee 1 thinks highly of our paper. We have added data that address the comments that were raised -see below.
1) ALS is characterized by progressive axonal dysfunction and recent data in fly showed that VAPB is involved in axonal expression of Down syndrome cell adhesion molecule. Here the authors only show dendritic defects. It would be important to also document in more details if there is or not an axonal phenotype (with specific markers) when impairing Yif1A and VAPB.
We fully agree with the reviewer and have performed YIF and VAP knockdown experiments in young neurons (DIV5) to be able to quantify axonal length (by means of tau staining) (see Fig. 7 ). In line with the mentioned Drosophila data we find a decrease in axonal length for both YIF and VAP knockdown. Our data demonstrate that VAP and YIF are required for the membrane delivery in the dendritic early secretory pathway. We agree with the referee that it is not clear whether YIF impairment leads to a specific transport defect or a more global inhibition of membrane delivery. We therefore tested the role of YIF and VAP in the 5-HT receptor trafficking. We obtained the YFP-tagged 5-HT1A receptor construct from Dr. Darmon (as used in Carrel et al., JNS, 2008) , repeated the localization experiments but could not find evidence for a role of YIF or VAP in the dendritic localization of 5HT1A receptors (Supplemental Figure 5) . We have no clear explanation for the discrepancy between our results and the data from the Darmon lab. One option is that YIF1B functions in a different context with 5-HT1A, which is not necessarily at the level of ER-to-Golgi trafficking. A recent study from the Darmon lab proposed that YIF1B acts as a scaffolding complex that recruits 5-HT1A into Rab6-labeled post-Golgi vesicles (Al Awabdh et al., 2012) . In addition to the results on 5HT1A receptor trafficking, we have -so far -not been able to observe transport impairments of other specific receptors / transmembrane proteins. It is possible that defects in the transport of specific proteins under the influence of VAP or YIF knockdown are difficult to measure as other transport routes can take over or act as default pathways. For example it has been hypothesized that specific proteins can reach the plasma membrane unconventionally by bypassing the Golgi (reviewed by Grieve and Rabouille, Cold Spring Harb Perspect Biol., 2011). These options are now more extensively discussed in the revised manuscript. 
2) Yif1B was

interacts also with mutant (P56S) VAPB and remains trapped in the aggregates generated by the mutant protein, the authors suggest that interferance with ER to Golgi trafficking may partly account for the pathogenicity of ALS-linked P56S-VAPB.
This is an interesting study with novel observations that may shed light on the role of the VAPs in membrane traffic and that proposes an interesting disease mechanism of mutant, ALS-linked, VAPB. Despite the interest, I have several major concerns plus a number of minor points, which must be addressed before the paper is suitable for publication.
We are pleased that Referee 2 thinks our findings are novel and of interest. We have added data that address the comments that were raised -see below.
Major concerns: 1) Role of the transmembrane domains in the YIF1A-VAPB interaction. From the wording of the section "The transmembrane domains of both VAPB and YIF1A are required for their interaction" (p. 5), it is not clear to me whether the authors are concluding that there is a specific interaction between the TMs of the interacting proteins, or whether the TMs, by allowing insertion of the proteins into the ER membrane and restricting their diffusion to a twodimensional space, simply facilitate their interaction. From Fig. 2E, it is clear that the N-terminal cytosolic portion of YIF1A by itself does not interact with ER-bound VAPB, while constructs carrying all four, or the last two, YIF1A TMs do. The contribution of the cytosolic and luminal loops in these constructs to this interaction is not considered; furthermore, one wonders how the GFP-
YIF1A construct with the first two TMs (complementary to the one with the last two) will behave. Is there any sequence specificity?
In the revised manuscript, we have improved the biochemical characterization of the VAPB-YIF1A interaction (Figure 2) . First, consistent with the SOSUI secondary structure predictions (Hirokawa et al., Bioinformatics 1998), we show that the N-terminal region of YIF1A is facing the cytosol and that two of the loops (between TM1-2 and TM3-4) reside in the ER lumen ( Figure 2B ). Second, our biochemical experiments show that the first two transmembrane domains (TM1-2; amino acid 131-198) are sufficient for VAPB binding. Third, the N-terminal cytosolic region, transmembrane domain TM3-4 and the cytosolic loop present between TM3 and TM4, are not required for the interaction with VAPB. Fourth, the single VAPB transmembrane domain is sufficient to bind YIF1A. Fifth, VAPB has almost no luminal structure, therefore an interaction with the luminal loop of YIF1A between TM1 and TM2 seems unlikely. We therefore conclude that TM domains most likely provide the primary driving force for the VAPB-YIF1A interaction. Moreover, the marked difference between binding of TM1-2 compared to TM3-4 suggest a specific interaction between the interacting proteins.
To further explore the binding of YIF1A with VAPB we mutated two GxxxG motifs that are present in TM1 and TM3 of YIF1A. The GxxxG motif is a common motif for interaction of two transmembrane helices and also VAPB contains a GxxxG motif in its transmembrane domain (Kim et al., J Biol Chem 2010). However, this GxxxG sequence seems not to be essential for VAP-YIF1A binding as disruption of these motifs in YIF1A did not interfere with VAPB binding. The role of other (specific) sequence motifs that mediate the YIF1A-VAPB interaction should be tested in future experiments.
Similarly, the involvement of VAPB's TMD is inferred from the pulldown of HA-YIFA by a construct in which GFP is fused to only the TMD of VAPB. It appears, however, that the pulldown of YIF1A by this construct is far less efficient than when the full-length VAPB is used as bait (Fig. 2H and I), suggesting that VAPB regions in the cytosolic domain are involved in the interaction. The control that is missing here is a VAPB construct with an unrelated TM. A useful experiment would be to express the P56S mutant containing an unrelated TM. Such constructs are known to form ER inclusion bodies; these should no longer be enriched in YIF1A if the interaction is crucially dependent on the VAP TMD.
We performed the suggested experiments and now show in Figure 9B that VAPB-P56S mutants containing an unrelated TM domain form inclusion bodies that do not recruit YIF1A. This confirms our biochemical data (Figure 2 ) and shows that YIF1A recruitment depends on the specific interaction with the transmembrane domain of VAPB-P56S. Figs. 5, 7, and 8, the (Fig. 1) .
A further important question concerns the interaction of YIF1A with the VAPB homologue VAPA: in the experiments of
We agree that these interactions need to be analyzed. We added extra biochemical data to Figure  1B ,C demonstrating that VAPA is able to interact with both YIF1A and YIF1B. In addition we transfected COS cells with VAPA-P56S, a construct that induces the formation of mutant inclusions similarly to VAPB-P56S (Teuling et al., J Neurosci 2007) and found that mutant VAPA aggregates are enriched in YIF1A and YIF1B ( Figure 1H, I ). (Figs 5, 7, 8 We have now added extra data to the revised manuscript showing that a second set of independent YIF and VAP shRNAs give similar morphological phenotype (Supplementary Figure 3) . In addition we included immunofluorescence data that show the efficiency of the VAP knockdown constructs in neurons (Supplementary Figure 2) . Unfortunately we were not able to determine the efficiency of the YIF shRNAs. We tested several commercially available YIF1A antibodies (2 antibodies from Santa Cruz and 1 from Sigma) but none of them was able to detect YIF1A in neuronal cells. We also generated rabbit polyclonal YIF1 antibodies ourselves but without any success.
2) Silencing experiments
Co-transfection of GFP-tagged constructs to select for neurons targeted by shRNAs is a standard method in our lab (van Spronsen et al., Neuron 2013; Schlager et al., EMBO J 2010; Jaworski et al., Neuron 2009 ). We use Lipofectamine 2000 for optimal neuronal transfection (Kapitein et al. Methods Cell Biol. 2010) and co-transfect GFP and shRNA construct at a 1:4 ratio to obtain optimal knockdown conditions in GFP positive neurons. To be absolutely sure about the high efficiency of co-transfection, we performed several control experiments in which mRFP-tagged constructs are co-transfected with GFP-tagged pSuper. In all these experiments, 100% of transfected neurons express both constructs. (Fig. 8) . Despite the fact that these experiments are carried out along the lines of work previously published in a prestigious journal (Ye B et al, Cell, 2007) 
3) Role of VAP A/B, YIF1A/B and SAR1A/B in membrane trafficking to dendrites
, I find that the interpretation of the results is ambiguous. The authors analyse recovery from the soma of a surface protein bleached in a dendrite, and find that recovery is reduced after silencing of VAPA/B, YIF1A/B or SAR1A/B. The problem is that there is more than one source of the dendritic surface protein (CD8-GFP); one expects that in the cell body most of it is on the surface, so that recovery into dendrites would depend on diffusion from the cell body plasmamembrane to the dendritic plasma membrane; some CD8 may be intracellular but past the ER, and also in this case, one does not expect a role for proteins involved in ER to Golgi transport. About 65% of the dendritic CD8 fluorescence recovers in only 20 minutes under control conditions;
it is difficult to think that over one third of this is due to vesicular transport, as would be suggested by the results in Sar1 silenced cells (Fig. 8C) . This would imply an extremely rapid turnover of dendritic CD8 (over 20% of dendritic CD8 replaced in 20 min In the revised manuscript, we included several controls for the GFP-CD8 FRAP experiments and found that most of the CD8 recovery is due to intracellular motility (Supplementary Figure 5) . First, we quantified the ratio of surface vs total CD8 in fixed cells and show that the relative amount of surface CD8 is very low (Supplementary Figure 5C) . Moreover, by adding rhodamine-conjugated hCD8 antibody to the culture media we specifically labeled the extracellular GFP-CD8 present on the surface and analyzed the recovery after FRAP. We found that extracellular GFP-CD8 only partly recovers compared to total CD8 (Supplementary Figure 5B) , making it unlikely that surface CD8 plays a substantial role in total recovery. Second, to further test the involvement of the early secretory pathway in CD8 trafficking we incubated the neurons with BFA and analyzed the recovery after FRAP. The data clearly show that BFA treatment has a marked effect on the dendritic CD8 recovery (Supplementary Figure 5D) , which is consistent with the paper of Ye et al, showing that ER to Golgi transport plays a significant role in CD8 trafficking. Third, since cycloheximide treatment did not affect CD8 recovery we exclude a role for local protein synthesis in this pathway We added scale bars to each figure. (Fig. 2) the amount of input, compared to the pulled down material, is not specified. Why is the input lane of (Fig. 2F) 
In the pulldown experiments
empty?
The ratio between input and immunoprecipitated pellet is now mentioned in the legends. We apologize for the missing input lane and replaced the figure by a better blot that includes an input (now figure 2D) 3. GST-VAPB pulldown experiments (Fig. 2H) : from the literature it is well known that VAPB-P56S is totally insoluble in non-denaturing detergents. Therefore, the use of glutathione beads to pull down this construct is completely unspecific, as the insoluble construct will pellet anyway, whether the beads are present or not.
In the new manuscript we now added an additional biotin pull-down experiment showing that VAPB-P56S is able to pull down YIF1A but not the N-terminal part of YIF1A. To increase solubility of VAPB-P56S we incubated 2h at 20°C before lysis (described by Teuling et al. 2007) . We added this information to the Material and Methods.
The ordinates of the graphs of Figs. 4E, 5G, 6D are cut at 0.5 (do not originate from 0). I am not sure whether this practice is accepted by EMBO J.
We have cut the y-axis at 0.5 for clarity and could not find specific information about 'the rules' for chart graphs in the EMBO J guides to authors. If EMBO J does not accept this type of graph we can adjust the y-axis or report the values in the result sections or in a supplementary Table.
Legend to Fig. 1: does the control consist of cells transfected with BirA alone, or of cells transfected with a control bio-GFP construct, as stated on p. 5?
The control consists of cells transfected with BirA and a control bio-GFP ( Figure 1A and B) . We added this to the legend.
Legend to Figure 3: the lettering B'-E' is not present on the figure.
We added B'-E' to the figure.
Results p.9: fourth to last line: should read "while in cells transfected with wild-type VAPB"
We changed this in the new manuscript.
Discussion p. 13: Line 8: Tran et al found no effect of VAPB silencing on VSVG transport.
We removed this reference.
9. Discussion p. 13: Fifth to last line: Teuling et al. (2007) reported that ubiquitin does NOT accumulate in P56S-VAPB aggregates.
We removed this reference. Fig. 2B versus Supp Fig. 1A . The same construct ) has a very different localization when cotransfected with Myc-VAPB (Fig. 2B) or Myc-VAPB-P56S (Supp. Fig. 1 We agree with the referee that the images used in the previous figures show very different localization of . Looking back at our original data, nuclear ("soluble") as well as vesicular ("small aggregates") localization of YIF1A can be seen. The localization of the GFP-YIF1A(1-131) does not depend on the co-expression of wildtype or mutant VAPB; when comparing cells with equal expression levels we do not see a shift in GFP-YIF1A(1-131) localization. However, the distribution pattern of the GFP-YIF1A(1-131) mainly depends on expression level; low expressing cells show accumulation in the nucleus, while high expressing cells often start to form small GFP-YIF1A vesicles/aggregates in the cytoplasm. In the revised manuscript we now substituted the image in Fig 2B (now Figure 2J ) for an image with low GFP-YIF1A(1-131) expression levels. In conclusion, using biochemical and immunofluorescent experiments we do not find evidence for interaction between the N-terminal cytosolic domain of YIF1A and VAPB. Fig. 8D : The effect of VAP depletion is less pronounced than that of YIF1A/B and of Sar1A/B), although significantly different from the control by Student's t test (Fig. 8D) . Given that four groups are involved, it would be better to apply Anova analysis.
10.
11.
In the revised manuscript, we performed more thorough statistical analysis on the FRAP data. First, we performed a repeated measure ANOVA and could show that the fluorescent recovery curves are significantly different (see legends Figure 8C ). Second, we applied ANOVA analysis on the maximal recovery data shown in Figure 8D and show that all groups are significantly different from the control. Figure 3 : the authors refer to the P56S-VAPB induced inclusion bodies as "tubular ER-like inclusions . Recent work has shown that these inclusions correspond to packed cisternae and not to tubules (see Papiani G. et al., J. Cell Sci 2012 for the 3D reconstruction of these structures by tomography). Furthermore, FRAP experiments definitely demonstrated the continuity of these structures with the remaining ER (Fasana E. et al, FASEB J 2010) . Therefore, "tubular ER -like inclusion" does not correctly describe the structures. Similarly, the cartoon of Sup. Fig. 3 , which shows the mutant VAPB aggregate as separate from the remaining ER, is incorrect.
Abstract, Introduction p. 3, and Supplemental
Although earlier work of Teuling et al. showed that VAPB-P56S accumulates in inclusions containing smooth ER-like tubules, recent work indeed suggests that VAPB-P56S inclusions in nonneuronal cells predominantly consist of a special form of stacked ER (see Fasana et al., 2010; Papiani et al., 2012) . We modified the revised manuscript and removed the word "tubular" from the abstract. In the introduction we included the work of Papiani et al "P56S mutant VAPB accumulates in inclusions that contain abnormal organized ER (Papiani et al, 2012; Teuling et al, 2007) .. etc". We also modified the cartoon (now Supplementary figure 7) depicting mutant VAPB aggregates as continuous with the ER. Figure 9 and Discussion: the idea that one pathogenic mechanism of P56S-VAPB may be to trap YIF1A in aggregates and consequently interfere with ER to Golgi transport is very appealing. When discussing this idea, the authors should, however, recognize that they observe this trapping effect under conditions of high overexpression of the mutant protein, and that the relevance of this observation to the situation of the heterozygous human subject remains to be determined.
13.
We added an extra sentence to the discussion: "Although the relevance of our observations to heterozygous patients remains uncertain (as our observations are under conditions of overexpression), our model suggests that mislocalization of YIF1A..etc" Thank you for submitting your revised manuscript to the EMBO Journal. Your study has now been re-reviewed by the two referees.
As you can see below, both referees appreciate the introduced changes and support publication here. Referee #2 has a few remaining points. Most of these can be resolved with adequate text changes including point #2. Also I would like to see that more of the materials and methods section is part of the main manuscript. Don't worry about the character count and try to place all relevant info in the main article file.
Once we get these last issues resolved then we will proceed with the acceptance of the paper for publication here.
Thank you for submitting your interesting study to the EMBO Journal.
